mTOR dependent transformed human cells have a distinct set of essential genes from bcr-abl transformed cells
暂无分享,去创建一个
[1] K. Guan,et al. mTOR as a central hub of nutrient signalling and cell growth , 2019, Nature Cell Biology.
[2] J. Murray,et al. Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression , 2018, Cancers.
[3] HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma , 2017, Cancer & metabolism.
[4] D. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[5] M. Colombi,et al. An Isogenic Cell Panel Identifies Compounds That Inhibit Proliferation of mTOR-Pathway Addicted Cells by Different Mechanisms , 2014, Journal of biomolecular screening.
[6] M. Climent,et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Qi-Lian Liang,et al. Function and expression of prolyl hydroxylase 3 in cancers , 2013, Archives of medical science : AMS.
[8] M. Hall,et al. HIF-independent role of prolyl hydroxylases in the cellular response to amino acids , 2012, Oncogene.
[9] P. Wysocki. mTOR inhibitors in renal cell carcinoma , 2011 .
[10] D. Cho,et al. mTOR inhibitors in renal cell carcinoma. , 2011, Therapy.
[11] C. Schaefer,et al. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction , 2011, Oncogene.
[12] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[13] Sang Gyun Kim,et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.
[14] M. Colombi,et al. Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants , 2006, Oncogene.
[15] Razelle Kurzrock,et al. Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics , 2003, Annals of Internal Medicine.
[16] C. Moroni,et al. Reversible abrogation of IL‐3 dependence by an inducible H‐ras oncogene. , 1989, The EMBO journal.
[17] S. Collins,et al. Replacement of serum by insulin and transferrin supports growth and differentiation of the human promyelocytic cell line, HL-60. , 1980, Experimental cell research.